Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Conditions
Interventions
Cisplatin
Paclitaxel
Locations
20
United States
University of Alabama
Birmingham, Alabama, United States
Indiana University- Simon Cancer Center
Indianapolis, Indiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
South Shore Hospital
Weymouth, Massachusetts, United States
Start Date
April 1, 2014
Primary Completion Date
January 1, 2019
Completion Date
August 1, 2020
Last Updated
September 30, 2025
NCT06681064
NCT05005403
NCT06547840
NCT06649331
NCT07029399
NCT04585750
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions